Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease

Area of Science:

• Medical research
• Microbiology
• Pulmonology

Background:

• Refractory Mycobacterium abscessus lung disease presents a significant clinical challenge.
• Intravenous phage therapy can induce anti-phage neutralizing antibodies.

Purpose of the Study:

• To evaluate the efficacy of phage nebulization in an elderly patient with refractory Mycobacterium abscessus lung disease.
• To assess the impact of pre-existing anti-phage antibodies on treatment outcomes.

Main Methods:

• Administration of phage nebulization to a patient with Mycobacterium abscessus lung disease.
• Monitoring of clinical parameters including weight, C-reactive protein, and Mycobacterium burden.
• Assessment of sputum neutralization capacity and phage resistance.

Main Results:

• Phage nebulization led to transient weight gain and decreased C-reactive protein levels.
• A reduction in Mycobacterium burden was observed following phage nebulization.
• Weak sputum neutralization capacity was noted, potentially limiting treatment efficacy.

Conclusions:

• Phage nebulization is a potential therapeutic approach for Mycobacterium abscessus lung disease.
• Anti-phage antibodies may impact treatment outcomes, necessitating further investigation.
• Phage resistance was not identified as a limiting factor in this case.